ALLY
ALLY
Company information not available. Track real-time insider trading activity, SEC Form 4 filings, and executive stock transactions.
Insider Buys
5
$3.50M
Insider Sales
6
$4.16M
Total Volume
$7.66M
11 transactions
Net Activity
$662K
Net selling
Sentiment Rating
Strong AccumulationCEO Conviction Index
High Conviction Accumulation
Key Drivers
- •Balanced trading volume with net neutral buying and selling activity.
- •Minor cluster buying: 2 unique insiders purchased shares.
- •CEO buying activity detected. When chief executives put their own money at risk, it is historically a strong bullish signal.
- •CFO buying activity detected. Statistical studies show CFO purchases have high predictive power due to their direct visibility into balance sheet details.
- •High accumulation: total purchase value exceeds $1M.
Score Methodology
The Insider Confidence Score (1-100) measures executive conviction. Starting from a neutral 50, it adjusts based on:
- +15Strong Buy Ratio: Purchases > 70% of volume (or up to -15 for heavy sales).
- +20Cluster Buying: ≥3 unique insiders buying within a 30-day window.
- +15CEO Buying: CEO committing own capital shows high conviction.
- +10CFO Buying: CFO purchasing shares shows financial alignment.
Rhodes Michael George
CEO
$1.99M total
Timmerman Douglas R.
Pres, DFS
$1.79M total
Patterson Kathleen L.
Chief HR, Corp Citizenship
$1.68M total
Hutchinson Russell E.
CFO
$1.51M total
Richard Stephanie N
Chief Risk Officer
$689K total
Quick Actions
ALLY has an insider buy conviction of 46%, compared to the Unknown sector buy average of 6%.
Over the last 90 days, corporate insiders at ALLY (ALLY) engaged in a total of 11 transactions reported via SEC Form 4 filings. Among these, 5 were open-market purchases and 6 were sales. The total volume of insider trading reached $7.66M.
The net insider activity for ALLY shows a net selling bias of $662K. This activity represents a 46% buy ratio, suggesting that insiders are currently neutral on the company's near-term outlook relative to recent history.
The most notable individual transaction was a Sale by Timmerman Douglas R. (Pres, DFS), who traded 39.7K shares valued at $1.79M on Apr 17, 2026.
Ally Financial (ALLY) Stock Looks Below Fair Value As Its 51% Run Continues
ALLY: Core-franchise growth and portfolio remixing underpin the path to mid-teens ROE
Price-Driven Insight from (ALLY) for Rule-Based Strategy
59% of Gen Z sports fans cut back on essentials; 55% delay savings and 56% take extra work
Ally Financial: Q3 Delivered On The Three Things I Said I'd Watch
ALLY Stock Slides 2.4% as Q2 Earnings Lag on Higher Provisions & Costs
Related News & Analyst Reports
Read original insights and educational research covering ALLY and the Unknown sector.
The AI Circular Valuation Bubble: Inside the Venture-Cloud Loop
An in-depth investigation into how technology giants and AI startups engage in circular capital flows, investing venture capital in exchange for cloud services and hardware, creating a closed-loop economy that artificially inflates valuations.
Sequoia Capital and the Mechanics of Venture Lock-Up Extensions
Sequoia Capital pioneered the use of voluntary lock-up extensions to signal portfolio company confidence. This report analyzes the market-price impact of Sequoia extension announcements and whether they have historically justified the delay.
The Role of Insider Trading in M&A: Deciphering the Pre-Merger Signals
M&A deals are the most fertile ground for illegal insider trading, and for legal cluster buys that signal a company is strategically attractive. This guide separates the legal signal from the illegal noise in M&A-adjacent Form 4 activity.
Venture-Backed Biotech IPOs: Inside the 2026 Buying Spree
2026 saw a resurgence of venture-backed biotech IPOs, accompanied by unusually high post-lockup insider buying. This report documents the specific Form 4 cluster events, purchase sizes, and 90-day price performance across a dozen recent biotech offerings.
Biotech Insider Buying: Analyzing Clinical Trial Catalysts
Biotech insiders walk a legal tightrope near trial readouts. This report identifies statistically significant buying clusters at small-cap biotechs 30-90 days before Phase 2 and Phase 3 data announcements.
Deciphering Option Exercises (Code M) vs. Open Market Purchases (Code P)
Transaction code M (option exercise) is often mistaken for bullish conviction, but it usually means nothing. Learn why Code P open-market purchases are the only Form 4 entries that signal genuine insider belief.
FAQs About ALLY Insider Trading
Answers to common questions regarding corporate filings and executive sentiment for ALLY.